Cancer Articles, News & Research Info | Treatment & Drug Trials - Cancer Therapy Advisor

Top News

Survival Gains From ICIs “Modest” Among Older Patients With NSCLC

Larotrectinib Bests Standard Care for TRK-Fusion Positive Cancers

Neoadjuvant Chemotherapy Improves Colon Cancer Outcomes

Adjuvant ICI Therapy Provides DFS Benefit in Certain Patients With RCC

Black Women Who Are Smokers at Breast Cancer Diagnosis Face Higher Risk of Death

Biden to Lift COVID-19 Emergency Measures in May

AI Can Screen Cancer Patients for Trial Enrollment More Efficiently

Many Cancer Patients Are Not Screened for Transportation Insecurity, Survey Suggests

Ganitumab Provides No Benefit in Metastatic Ewing Sarcoma

Esophageal, Gastric Cancer Risks Reduced With Bariatric Surgery for Obesity

Many Women May Underestimate Cancer Risk Associated With Breast Density

Comorbidity Burden Predicts Survival in Acute Promyelocytic Leukemia

EDITORIAL ADVISORY BOARD

Barbara Ann Burtness, MD

Steven Cohen, MD

E. David Crawford, MD

Don S. Dizon, MD, FACP

Jeffrey M. Farma, MD

Neal D. Shore, MD, FACS

Mark A. Socinski, MD

Mario Sznol, MD

Click here for complete profiles

Featured

Aggregating Data Hides Cancer Disparities Affecting Asian and NHPI Patients in the US

Aggregated data can hide disparities in cancer incidence and outcomes among Asian and Native Hawaiian/Pacific Islander patients in the US.
ASCO GI 2023

News coverage from the ASCO Gastrointestinal Cancers Symposium
ACS Report Shows Prostate Cancer on the Rise, Cervical Cancer on the Decline

A report from the American Cancer Society reveals trends in cancer incidence and mortality over time and includes projections for 2023.
Improving End-of-Life Discussions With Cancer Patients

Timely discussions about end-of-life preferences can ensure patients with advanced cancer receive care that aligns with their goals, experts say.
ASH 2022: MCL Trials Break New Ground, May Change Practice

Mantle cell lymphoma trials presented at ASH 2022 have broken new ground, shown promising results, and may change practice, according to researchers.
ASH 2022: Promising Results in Newly Diagnosed and Relapsed/Refractory Multiple Myeloma

The MonumenTAL-1, MajesTEC-2, OPTIMUM/MUKnine, and GMMG-CONCEPT trials have shown promising results for patients with newly diagnosed or relapsed/refractory multiple myeloma.
AML Research From ASH 2022: Novel Combinations and Evidence That “Less is More”

AML research presented at ASH 2022 highlighted promising combination regimens and suggested that some patients may benefit from less intensive treatment.
CAR-T Therapy in Pediatric Leukemia: Past, Present, and Future

Prior to the introduction of CAR T-cell therapy, pediatric patients with ALL had limited treatment options for relapsed or refractory disease.
ASH 2022: New Findings in CLL

Research in patients with CLL showed that zanubrutinib can outperform ibrutinib, a triplet is effective for high-risk CLL, cell death may predict the depth of response, and a CAR T-cell therapy is likely not an option for CLL patients.

More Features

Breast cancer

SABCS 2022: Trials Show Improved Outcomes in HR+, HER2- Breast Cancer

By

Alan P. Lyss, MD

ASH 2022: Trials Show Promising Results in Follicular Lymphoma

By

Jonathan Goodman, MPhil

multiracial group racism implicit bias race

Differences in Tumor Biology Could Partly Explain Disparities in Metastatic NSCLC

By

Alan P. Lyss, MD

Cancer patient in pain

Recognizing Radiation Therapy as Both Cause and Treatment for Cancer Pain

By

Bryant Furlow

Examining the Pharmacoeconomics of Advanced Prostate Cancer

Medicine vs Food: The Patient Care Dilemma of Financial Toxicity

By

Jody A. Charnow

More Features »

Fact Sheets

Vaccination

Fact Sheet: COVID-19 Vaccine Considerations for Patients With Cancer

COVID-19 testing

What to Expect: Enrolling on a Cancer Clinical Trial During COVID-19